Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection

US8518408B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITE DE STRASBOURG · FR

Inventors

• Thomas Baumert · Glückstadt, DE
• Catherine Schuster · Strasbourg, FR
• John F. Thompson · Minneapolis, US
• Fritz Grunert · Glückstadt, DE

Key dates

• Filing date: Sep 25, 2009
• Grant date: Aug 27, 2013
• Expiry date: Mar 10, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.